CN101686973B - 应用4-氨基喹啉-3-腈治疗抗伊马替尼的白血病 - Google Patents

应用4-氨基喹啉-3-腈治疗抗伊马替尼的白血病 Download PDF

Info

Publication number
CN101686973B
CN101686973B CN2008800219346A CN200880021934A CN101686973B CN 101686973 B CN101686973 B CN 101686973B CN 2008800219346 A CN2008800219346 A CN 2008800219346A CN 200880021934 A CN200880021934 A CN 200880021934A CN 101686973 B CN101686973 B CN 101686973B
Authority
CN
China
Prior art keywords
leukemia
methoxy
treatment
imatinib
bcrabl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008800219346A
Other languages
English (en)
Chinese (zh)
Other versions
CN101686973A (zh
Inventor
B·休斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101686973(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101686973A publication Critical patent/CN101686973A/zh
Application granted granted Critical
Publication of CN101686973B publication Critical patent/CN101686973B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2008800219346A 2007-06-01 2008-05-30 应用4-氨基喹啉-3-腈治疗抗伊马替尼的白血病 Active CN101686973B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
US60/932,650 2007-06-01
PCT/US2008/065215 WO2008150957A2 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Publications (2)

Publication Number Publication Date
CN101686973A CN101686973A (zh) 2010-03-31
CN101686973B true CN101686973B (zh) 2013-06-19

Family

ID=39639071

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800219346A Active CN101686973B (zh) 2007-06-01 2008-05-30 应用4-氨基喹啉-3-腈治疗抗伊马替尼的白血病

Country Status (23)

Country Link
US (1) US11103497B2 (https=)
EP (4) EP2152267A2 (https=)
JP (3) JP5888853B2 (https=)
KR (1) KR101493543B1 (https=)
CN (1) CN101686973B (https=)
AU (1) AU2008260070B9 (https=)
BR (1) BRPI0812355A2 (https=)
CA (3) CA2964162C (https=)
CL (1) CL2008001577A1 (https=)
CY (2) CY1115251T1 (https=)
DK (2) DK2478905T3 (https=)
ES (2) ES2881391T3 (https=)
HU (1) HUE055524T2 (https=)
IL (1) IL202407A0 (https=)
MX (1) MX2009013069A (https=)
PA (1) PA8782301A1 (https=)
PL (2) PL2478905T3 (https=)
PT (2) PT2478905E (https=)
RU (1) RU2464026C2 (https=)
SI (2) SI2478905T1 (https=)
TW (1) TW200908982A (https=)
WO (1) WO2008150957A2 (https=)
ZA (1) ZA200908480B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2964162C (en) 2007-06-01 2019-12-31 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
SG192769A1 (en) 2011-03-04 2013-09-30 Glaxosmithkline Ip No 2 Ltd Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
RU2662810C2 (ru) 2013-02-21 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Хиназолины в качестве ингибиторов киназы
KR101733665B1 (ko) 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用
WO2025024311A2 (en) * 2023-07-21 2025-01-30 Icahn School Of Medicine At Mount Sinai G9a/glp inhibitors and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101780A1 (en) * 2003-11-06 2005-05-12 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
PT2017335E (pt) 2001-10-05 2011-03-02 Novartis Ag Domínios da cinase abl mutados
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
DE602006014540D1 (en) * 2005-05-16 2010-07-08 Irm Llc Pyrrolopyridinderivate als proteinkinaseinhibitoren
EP1904654A2 (en) 2005-07-15 2008-04-02 Brystol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
BRPI0616923A2 (pt) 2005-10-06 2011-07-05 Lilly Co Eli anticorpos monoclonais, seus usos e composição farmacêutica
EP1948820A2 (en) * 2005-11-04 2008-07-30 Bristol-Myers Squibb Pharma Company T315a and f317i mutations of bcr-abl kinase domain
CA2964162C (en) 2007-06-01 2019-12-31 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101780A1 (en) * 2003-11-06 2005-05-12 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic cells;Miriam Puttini et al;《Cancer Research》;20061201;第66卷(第23期);11320-11321 *

Also Published As

Publication number Publication date
SI3002009T1 (sl) 2021-09-30
RU2009144128A (ru) 2011-07-20
RU2464026C2 (ru) 2012-10-20
PA8782301A1 (es) 2009-01-23
IL202407A0 (en) 2010-06-30
HK1142812A1 (en) 2010-12-17
EP3002009A3 (en) 2016-07-06
BRPI0812355A2 (pt) 2015-01-27
CN101686973A (zh) 2010-03-31
CA2964162C (en) 2019-12-31
CY1124391T1 (el) 2022-07-22
EP3002009A2 (en) 2016-04-06
TW200908982A (en) 2009-03-01
MX2009013069A (es) 2010-03-17
EP2152267A2 (en) 2010-02-17
DK3002009T3 (da) 2021-08-02
ES2881391T3 (es) 2021-11-29
CY1115251T1 (el) 2017-01-04
CA2688467C (en) 2015-05-12
JP2010529038A (ja) 2010-08-26
EP2777704A2 (en) 2014-09-17
AU2008260070B2 (en) 2011-08-18
KR20100017983A (ko) 2010-02-16
CA2868899C (en) 2017-06-13
EP2478905A3 (en) 2013-01-16
ES2477567T3 (es) 2014-07-17
JP2016074700A (ja) 2016-05-12
AU2008260070B9 (en) 2012-01-19
ZA200908480B (en) 2010-08-25
US11103497B2 (en) 2021-08-31
CA2688467A1 (en) 2008-12-11
EP3002009B1 (en) 2021-07-07
CA2964162A1 (en) 2008-12-11
HUE055524T2 (hu) 2021-11-29
PL2478905T3 (pl) 2014-10-31
WO2008150957A3 (en) 2009-08-06
JP5888853B2 (ja) 2016-03-22
PL3002009T3 (pl) 2021-12-13
KR101493543B1 (ko) 2015-02-13
US20080318971A1 (en) 2008-12-25
SI2478905T1 (sl) 2014-07-31
CA2868899A1 (en) 2008-12-11
EP2478905B1 (en) 2014-05-14
AU2008260070A1 (en) 2008-12-11
PT2478905E (pt) 2014-07-16
JP2014111629A (ja) 2014-06-19
DK2478905T3 (da) 2014-06-30
WO2008150957A2 (en) 2008-12-11
EP2777704A3 (en) 2015-01-21
CL2008001577A1 (es) 2008-07-25
PT3002009T (pt) 2021-08-02
EP2478905A2 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
CN101686973B (zh) 应用4-氨基喹啉-3-腈治疗抗伊马替尼的白血病
CN104363913B (zh) Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
TWI734734B (zh) 一種ｅｇｆｒ/ｈｅｒ２受體酪氨酸激酶抑制劑在製備治療ｈｅｒ２突變癌症藥物中的用途
CN110678169A (zh) Chk1-抑制剂与weel-抑制剂的组合
JP7640033B2 (ja) ピリド［１，２－ａ］ピリミジノン類似体の使用
JP2007533655A (ja) 慢性骨髄性白血病（ｃｍｌ）の治療のための４−アニリノ−３−キノリンカルボニトリル
US20250161276A1 (en) Drug combinations and methods of treating ovarian cancer
HK1142812B (en) Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
WO2015188738A1 (zh) 依鲁替尼的新用途
WO2026086864A1 (zh) 一种kat6抑制剂的联合使用
US20190117652A1 (en) Combination of raf inhibitors and taxanes
US20240115582A1 (en) Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142812

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1142812

Country of ref document: HK